Pharma Trend Outlook: Pharma 4.0 and Industry Resilience
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain.
As we welcome in a new year with new possibilities, CPHI Online is proud to bring you the 2023 Pharma Trends Outlook report in partnership with ACG World.
This Trend Report explores 12 trends predicted to shape the pharmaceutical landscape in 2023 and the implications they will have on all pharmaceutical players, including suppliers, research and development, manufacturing, and distribution. Some of the biggest trends covered include:
- The Data Revolution and Realities of Pharma 4.0
- Incentivising biotechnological innovation with excipients
- The true cost of APIs
- Re-shoring of pharma manufacturing
The pharmaceutical industry has witnessed a great many innovations and advancements in the last year. With 32 novel drug approvals to date, a bivalent COVID-19 vaccine, and the return of face-to-face events, the industry is primed to see the continuation of these positive developments. However, issues including supply chain disruptions, rising inflation, and global events such as the War in Ukraine have presented unprecedented challenges for the pharmaceutical industry, leaving all players feeling the pressures of these events.
In this Trend Report, we cover trends such as Pharma 4.0 and the Data Revolution, sustainability trends, pharmaceutical start-up initiatives, cell and gene therapies, and more with expert insight from across the pharmaceutical value chain. As we enter a post-pandemic world and face new global challenges, the pharma industry must be applauded for its pursuit of new products, technologies and solutions which ultimately improve the lives of people worldwide.
Register and download our full Trend Report to see what is in store for the pharmaceutical industry in 2023.
Keep updated with the latest in pharmaceutical trends with our 2024 Pharma Trends Outlook report. Download here.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...